Last updated: March 12, 2026
What is the drug identified as NDC 00168-0033?
NDC 00168-0033 represents a specific formulation of Adalimumab, marketed under the brand name Humira. It is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), used primarily for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
What is the current market size for Humira (NDC 00168-0033)?
Data indicates that Humira remains the top-selling biologic globally. For 2022, AbbVie reported worldwide Humira revenues exceeding $20 billion. The U.S. market accounts for approximately 50% of global sales, estimated at $10 billion annually.
Market growth factors include:
- Increasing prevalence of autoimmune diseases.
- Expansion of indications, including ankylosing spondylitis and hidradenitis suppurativa.
- Growing adoption in underserved markets.
How do existing competitors impact market share?
Key competitors include:
- Erelzi (etanercept-ykro) and Cimzia (certolizumab pegol)—subcutaneous TNF inhibitors.
- Skyrizi (risankizumab) and Taltz (ixekizumab)—IL-23 and IL-17 inhibitors, respectively.
- Biosimilars—such as Amjevita (Amgen/AbbVie), becoming increasingly available since 2023.
Biosimilar entries, notably by Amgen and Samsung Bioepis, are expected to erode branded Humira's market share by approximately 15% annually through 2025.
What are the price trends and projections?
Current Pricing (U.S. Market)
- Humira (age 18+): Approximate list price per two-dose pen (40 mg/0.4 mL) is $2,600.
- Per-injection cost: ~$1,300.
- Annual treatment costs: Approximately $30,000–$34,000 for a standard monotherapy, depending on dosing frequency.
Biosimilar Impact on Pricing
- Biosimilars launched in late 2023 at 20-30% lower price points.
- Initial biosimilar list prices range from $1,800 to $2,200 per dose.
- Price erosion expected to reach 35-50% by 2026, with generic-biologics competition continuing to intensify.
Future Price Projections
| Year |
Estimated Average Price Per Dose |
Notes |
| 2023 |
$2,200 |
Launch of biosimilars, initial discounts |
| 2024 |
$2,000 |
Increased biosimilar uptake, price competition |
| 2025 |
$1,800 |
Market stabilization, increased biosimilar penetration |
| 2026 |
$1,600 |
Further biosimilar competition, potential discounted pricing |
These price projections factor in biosimilar market growth, regulatory influences, and payer negotiations.
What are the regulatory and patent landscape implications?
- Patent expiry for Humira's U.S. patent portfolio occurred in 2023, opening the door for biosimilar competition.
- The FDA approved multiple biosimilars, with market entry occurring before patents fully expired.
- Market access varies by region; the U.S. sees aggressive biosimilar pricing, while Europe has seen higher price reductions.
How does market adoption influence sales volume?
- Prescriber acceptance of biosimilars in place of Humira remains variable, with some providers reluctant due to biosimilar interchangeability concerns.
- Estimated volume growth for biosimilars could reach 5–7% annually from 2024 through 2026.
- Improved healthcare provider education and payer policies are expected to accelerate biosimilar adoption.
What are the key opportunities and risks?
| Opportunities |
Risks |
| Expansion in emerging markets |
Market erosion from biosimilar competition |
| New indications approval |
Regulatory delays or restrictions |
| Improved formulations (e.g., auto-injectors) |
Patent litigations or legal challenges |
Conclusion
Humira (NDC 00168-0033) maintains a dominant market position, but biosimilar competition is rapidly diminishing its price and sales. Pricing is expected to decline by approximately 30-50% over the next three years, driven by biosimilar entry, payer pressure, and regional market dynamics. Companies with biosimilar products are positioned to capitalize on this decline through volume increases and strategic pricing.
Key Takeaways
- Revenue for Humira was over $20 billion globally in 2022.
- Biosimilars launched in late 2023 are causing an ongoing decline in list prices.
- Price per dose is projected to decrease from around $2,200 in 2023 to approximately $1,600 by 2026.
- Biosimilar competition is expected to reduce market share by 15-20% annually through 2025.
- Market expansion into new indications and regions presents growth opportunities, despite pricing pressures.
FAQs
Q1. Will the price of Humira recover post-biosimilar entry?
No. Biosimilar price competition tends to sustain long-term reductions, with minimal likelihood of rebounds unless new patents or formulations protect the brand.
Q2. Are biosimilar approvals in the U.S. universally accepted by providers?
Acceptance varies; some providers are cautious, but increasing familiarity and policies favoring biosimilar use are improving adoption.
Q3. How does patent litigation influence biosimilar market entry?
Patent litigations can delay biosimilar launches, but most biosimilar approvals occurred before patent expiries, minimizing delays.
Q4. What regional differences impact pricing and market share?
Europe and Asia see more aggressive biosimilar price reductions and higher market penetration compared to the U.S.
Q5. What are the key drivers of future revenue for biosimilar manufacturers?
Market penetration in chronic conditions, expansion into new indications, and regional growth are primary drivers.
Sources:
[1] AbbVie Annual Reports 2022.
[2] U.S. Food and Drug Administration. Biosimilar approvals and guidelines.
[3] IQVIA Data on biologic drug sales 2022–2023.
[4] Evaluate Pharma World Preview 2023.
[5] European Medicines Agency. Biosimilar market trends.
